Average Co-Inventor Count = 12.35
ph-index = 6
The patent ph-index is calculated by counting the number of publications for which an author has been cited by other authors at least that same number of times.
Company Filing History:
1. Pfizer Corporation (10 from 4,456 patents)
2. Nurix Therapeutics, Inc. (6 from 14 patents)
3. Cystic Fibrosis Foundation Therapeutics, Inc. (3 from 5 patents)
4. Cystic Fibrosis Foundation (3 from 3 patents)
22 patents:
1. 12234230 - Substituted benzyl-triazole compounds for Cbl-b inhibition, and further uses thereof
2. 12202836 - Bicyclic-fused heteroaryl or aryl compounds
3. 12049471 - Cyano cyclobutyl compounds for Cbl-b inhibition and uses thereof
4. 11951133 - 3-substituted piperidine compounds for Cbl-b inhibition, and use thereof
5. 11702424 - Bicyclic-fused heteroaryl or aryl compounds
6. 11530229 - Cyano cyclobutyl compounds for CBL-B inhibition and uses thereof
7. 11464802 - 3-substituted piperidine compounds for Cbl-b inhibition, and use thereof
8. 11401267 - Substituted benzyl-triazole compounds for Cbl-b inhibition, and further uses thereof
9. 10815213 - Bruton's tyrosine kinase inhibitors
10. 10793579 - Bicyclic-fused heteroaryl or aryl compounds
11. 10766904 - Bicyclic heteroaryl derivatives as CFTR potentiators
12. 10494374 - Pyrrolopyrimidines as CFTR potentiators
13. 10377762 - Bicyclic heteroaryl derivatives as CFTR potentiators
14. 10329302 - Bicyclic-fused heteroaryl or aryl compounds
15. 10316018 - Bicyclic-fused heteroaryl or aryl compounds as IRAK4 modulators